Covered recipient · General Payments record
ANITA KOHLI
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$164,175.61
71 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Grant | $140,000.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,311.00 | 6 |
| Consulting Fee | $4,370.00 | 1 |
| Food and Beverage | $2,368.33 | 54 |
| Travel and Lodging | $2,094.01 | 8 |
| Education | $32.27 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Madrigal Pharmaceuticals | $150,764.63 | 25 |
| Gilead Sciences, Inc. | $11,626.08 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,334.25 | 9 |
| Ipsen Biopharmaceuticals, Inc | $146.70 | 5 |
| ABBVIE INC. | $71.50 | 2 |
| PFIZER INC. | $69.19 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44.24 | 2 |
| Novo Nordisk Inc | $32.27 | 1 |
| Invivyd Inc | $24.02 | 1 |
| Mirum Pharmaceuticals, Inc. | $23.03 | 1 |
| ORPHALAN INC | $21.05 | 1 |
| Intercept Pharmaceuticals, Inc. | $18.65 | 1 |
Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANITA KOHLI
NPI 1619189800 · CMS profile ID 494839
Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease
CHANDLER, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1619189800?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANITA KOHLI, NPI 1619189800, CMS profile ID 494839. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619189800?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ANITA KOHLI, NPI 1619189800, CMS profile ID 494839. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619189800?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ANITA KOHLI, NPI 1619189800, CMS profile ID 494839, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619189800?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
71 matching records · $164,175.61 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–71 of 71.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | $27.21 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248278574 | CMS |
| Madrigal Pharmaceuticals | $89.88 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248278576 | CMS |
| Gilead Sciences, Inc. | $18.81 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234540999 | CMS |
| Madrigal Pharmaceuticals | $140,000.00 | 04/29/2025 | Grant | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248278572 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.71 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231802510 | CMS |
| Gilead Sciences, Inc. | $139.67 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234377750 | CMS |
| Ipsen Biopharmaceuticals, Inc | $15.64 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208861038 | CMS |
| Gilead Sciences, Inc. | $800.00 | 04/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234359505 | CMS |
| Intercept Pharmaceuticals, Inc. | $18.65 | 04/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249868677 | CMS |
| Ipsen Biopharmaceuticals, Inc | $18.20 | 03/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208861034 | CMS |
| Gilead Sciences, Inc. | $19.47 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234533919 | CMS |
| Invivyd Inc | $24.02 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240484864 | CMS |
| Ipsen Biopharmaceuticals, Inc | $61.54 | 03/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208861049 | CMS |
| Gilead Sciences, Inc. | $25.72 | 03/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234468281 | CMS |
| Madrigal Pharmaceuticals | $41.52 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248278570 | CMS |
| ABBVIE INC. | $13.84 | 02/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202221127 | CMS |
| Madrigal Pharmaceuticals | $47.82 | 02/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248278568 | CMS |
| Madrigal Pharmaceuticals | $39.40 | 01/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248278566 | CMS |
| Madrigal Pharmaceuticals | $2,115.00 | 01/17/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248278564 | CMS |
| Ipsen Biopharmaceuticals, Inc | $23.64 | 01/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208861031 | CMS |
| Gilead Sciences, Inc. | $5.55 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234600838 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $6,143,993.05 | 885 |
| PY2024 | Recipient | $726.56 | 1 |
| PY2024 | Principal investigator | $4,741,777.65 | 291 |
| PY2023 | Recipient | $620.01 | 1 |
| PY2023 | Principal investigator | $881,751.52 | 176 |
| PY2022 | Recipient | $21,000.00 | 2 |
| PY2022 | Principal investigator | $1,874,204.60 | 222 |
| PY2021 | Recipient | $666.19 | 5 |
| PY2021 | Principal investigator | $4,278,092.48 | 928 |
| PY2020 | Recipient | $150,049.96 | 2 |
| PY2020 | Principal investigator | $3,452,166.39 | 282 |
| PY2019 | Recipient | $67.00 | 1 |
| PY2019 | Principal investigator | $2,685,802.13 | 181 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
885 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $136.05 | 12/31/2025 | Non-covered Recipient Entity Arizona Clinical Trials | An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-8527 in Participants with Mild and Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1232938788 |
| Principal investigator 1 | Eli Lilly and Company | $5,634.00 | 12/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES (SYNERGY-OUTCOMES); N1T-MC-TZ01; N1T-MC-RT01 | No dispute reported | 06/30/2026 | 1187881826 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,881.65 | 12/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665868 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $71,702.55 | 12/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665873 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,224.40 | 12/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248254768 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $29.40 | 12/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248254772 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,613.40 | 12/19/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685015 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $839.16 | 12/19/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699610 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,100.20 | 12/19/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699634 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,675.28 | 12/19/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699642 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,188.08 | 12/19/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $839.16 | 12/19/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699658 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,044.00 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM | No dispute reported | 06/30/2026 | 1211665897 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $19,853.10 | 12/19/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285897 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,734.89 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254489 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,036.50 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254514 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $100.00 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254518 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,467.50 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254521 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254525 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $555.00 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254529 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,917.34 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254533 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $50.00 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254538 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,037.50 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254542 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254546 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,484.85 | 12/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184278784 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,159.75 | 12/18/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220802006 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 12/17/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 12/17/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699570 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 12/17/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699572 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.62 | 12/17/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699574 |
| Principal investigator 1 | Eli Lilly and Company | $915.38 | 12/17/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187881828 |
| Principal investigator 1 | Eli Lilly and Company | $934.02 | 12/17/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187882076 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,936.00 | 12/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665866 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,935.40 | 12/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248254168 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,600.00 | 12/15/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801976 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,170.40 | 12/15/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801978 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $131.04 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699510 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699512 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $252.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699514 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $294.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699516 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $154.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699518 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699520 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699522 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $252.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699524 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,200.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699526 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15,000.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699528 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $154.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699530 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.89 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699532 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699534 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $131.04 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699536 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699538 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $294.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699540 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $294.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699542 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,000.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699544 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699546 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,725.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699548 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $154.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699550 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $141.12 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699552 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,000.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699554 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699556 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699558 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $131.04 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699560 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.89 | 12/11/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699562 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $1,100.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285881 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $113.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285883 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $107.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285885 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $2,240.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285887 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $507.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285889 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $452.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285891 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $113.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285893 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $391.00 | 12/11/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285895 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,629.83 | 12/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253978 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $14,377.50 | 12/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253990 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $405.00 | 12/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253994 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,244.25 | 12/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184274240 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,759.40 | 12/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184274242 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 12/10/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220814045 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 12/05/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699600 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 12/05/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699618 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $120.00 | 12/05/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699620 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $420.00 | 12/05/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699638 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $84.00 | 12/05/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699644 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $84.00 | 12/05/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699660 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $16,640.00 | 12/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253579 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,406.00 | 12/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 12/04/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685017 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 12/04/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685019 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 12/04/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $850.00 | 12/04/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685023 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $600.00 | 12/04/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685025 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 12/04/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685027 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 12/04/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685029 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 12/04/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685031 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $17,168.00 | 12/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM | No dispute reported | 06/30/2026 | 1211665901 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,380.40 | 12/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248253418 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $105.00 | 12/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248253423 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,425.69 | 12/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253494 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,484.85 | 12/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184268901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,256.10 | 12/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184268903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.95 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699602 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $105.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699604 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $80.64 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699606 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699608 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699612 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $80.64 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699614 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $140.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699616 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $420.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699622 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $420.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699624 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $105.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699626 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699628 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $140.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699630 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $80.64 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699632 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699636 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699640 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $296.35 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699646 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.95 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699648 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699650 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $131.04 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699652 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.00 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699654 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.95 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699662 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $296.35 | 12/03/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699664 |
| Principal investigator 1 | ModernaTX, Inc. | $136.60 | 12/02/2025 | Non-covered Recipient Entity LiverHealth II DBA AZ ClinTrials | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999159 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694621 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694623 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694625 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694627 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694629 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694631 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220766378 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $37,912.05 | 12/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665878 |
| Principal investigator 1 | ModernaTX, Inc. | $410.40 | 12/01/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,613.40 | 11/27/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,613.40 | 11/27/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684993 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21,914.20 | 11/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699596 |
| Principal investigator 1 | ModernaTX, Inc. | $9,168.06 | 11/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999061 |
| Principal investigator 1 | ModernaTX, Inc. | $1,460.34 | 11/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999073 |
| Principal investigator 1 | ModernaTX, Inc. | $23,645.84 | 11/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999121 |
| Principal investigator 1 | ModernaTX, Inc. | $9,784.20 | 11/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999129 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 11/26/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699588 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15,000.00 | 11/26/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699590 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,200.00 | 11/26/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699592 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,000.00 | 11/26/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699594 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,000.00 | 11/26/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699598 |
| Principal investigator 1 | ModernaTX, Inc. | $117.00 | 11/26/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999091 |
| Principal investigator 1 | ModernaTX, Inc. | $201.60 | 11/26/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999127 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $872.00 | 11/25/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285873 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $678.00 | 11/25/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285875 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $1,629.00 | 11/25/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285877 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $1,356.00 | 11/25/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285879 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,580.29 | 11/25/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252972 |
| Principal investigator 1 | ModernaTX, Inc. | $273.20 | 11/24/2025 | Non-covered Recipient Entity LiverHealth II DBA AZ ClinTrials | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999109 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $9,937.80 | 11/20/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285871 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $270.00 | 11/20/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184263325 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,750.00 | 11/20/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184263357 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $432.00 | 11/20/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184263375 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $55.00 | 11/20/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184263409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 11/19/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699564 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 11/19/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699566 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 11/19/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699672 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 11/19/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699674 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $51,026.00 | 11/18/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220802004 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $49,622.30 | 11/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,716.15 | 11/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184261075 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $635.85 | 11/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184261077 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $660.00 | 11/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184261079 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,835.00 | 11/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184261081 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,185.10 | 11/13/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801972 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,137.00 | 11/13/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801974 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684987 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $500.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685005 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685007 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685011 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 11/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685013 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,408.00 | 11/12/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192185662 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,758.58 | 11/12/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192186964 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,990.43 | 11/12/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192186969 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $3,645.00 | 11/07/2025 | Non-covered Recipient Entity Arizona Clinical Trials | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285869 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $729.30 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252456 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $585.00 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252460 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $585.00 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252464 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,950.00 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252467 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,805.40 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252500 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $195.00 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252504 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,629.83 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252508 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,482.55 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184258107 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,484.85 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184258109 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.00 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184258111 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $702.00 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184258113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,750.00 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184258115 |
| Principal investigator 1 | ModernaTX, Inc. | $554.40 | 11/06/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999093 |
| Principal investigator 1 | ModernaTX, Inc. | $117.00 | 11/06/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,960.00 | 11/05/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,600.40 | 11/05/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,960.00 | 11/05/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,997.00 | 11/05/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,997.00 | 11/05/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685003 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,960.00 | 11/05/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685009 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,380.40 | 11/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248252310 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $17,759.00 | 11/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248252314 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,544.95 | 11/03/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220802002 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694609 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694611 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694613 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694615 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694617 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694619 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220766376 |
| Principal investigator 1 | ModernaTX, Inc. | $1,572.30 | 10/30/2025 | Non-covered Recipient Entity LiverHealth II DBA AZ ClinTrials | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999157 |
| Principal investigator 1 | Ardelyx, Inc. | $12,550.00 | 10/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults | No dispute reported | 06/30/2026 | 1247838740 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $140.00 | 10/29/2025 | Non-covered Recipient Entity Arizona Liver Health | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545579 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $525.00 | 10/29/2025 | Non-covered Recipient Entity Arizona Liver Health | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545581 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $122,545.00 | 10/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220801986 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,618.00 | 10/28/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192156558 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,323.00 | 10/27/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685033 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 10/27/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685035 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 10/27/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220685037 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 10/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694633 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.78 | 10/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694635 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $876.00 | 10/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694637 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.80 | 10/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694639 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22.08 | 10/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694641 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 10/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699666 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 10/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699668 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.00 | 10/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699670 |
| Principal investigator 1 | ModernaTX, Inc. | $8,823.54 | 10/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999103 |
| Principal investigator 1 | ModernaTX, Inc. | $6,848.94 | 10/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999105 |
| Principal investigator 1 | ModernaTX, Inc. | $4,655.48 | 10/24/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975907 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $1,101.60 | 10/23/2025 | Non-covered Recipient Entity Arizona Liver Health | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285701 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $7,000.00 | 10/23/2025 | Non-covered Recipient Entity Arizona Liver Health | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285703 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $1,500.00 | 10/23/2025 | Non-covered Recipient Entity Arizona Liver Health | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285705 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,105.06 | 10/23/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251964 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $750.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684967 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684969 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $600.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684973 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 10/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684975 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,000.00 | 10/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211665886 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $10,000.00 | 10/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211665890 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,783.00 | 10/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211665894 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $1,000.00 | 10/16/2025 | Non-covered Recipient Entity Arizona Liver Health | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285699 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,475.23 | 10/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251553 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,518.80 | 10/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248251562 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,969.70 | 10/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184250467 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $475.00 | 10/15/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801970 |
| Principal investigator 1 | Genentech, Inc. | $450.00 | 10/13/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211665882 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $2,425.50 | 10/09/2025 | Non-covered Recipient Entity Arizona Liver Health | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285697 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,950.46 | 10/09/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251443 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,031.10 | 10/08/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220801994 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,717.25 | 10/08/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220801996 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,496.85 | 10/08/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220801998 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,496.85 | 10/08/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220802000 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $940.95 | 10/03/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220801988 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $583.20 | 10/03/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220801990 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,040.95 | 10/03/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220801992 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $12,063.60 | 10/03/2025 | Non-covered Recipient Entity Arizona Liver Health | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | No dispute reported | 06/30/2026 | 1184285695 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,939.03 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251186 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $500.00 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251195 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $450.00 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251198 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $750.00 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251203 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,012.50 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251206 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $12,740.07 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248251211 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $996.55 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184244505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,945.95 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184244507 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $292.50 | 10/02/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248250830 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $305.50 | 10/02/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248250835 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $21,526.25 | 10/02/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248250842 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $175.00 | 10/02/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248250847 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694599 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694601 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694603 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694607 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220766374 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,075.00 | 10/01/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220801984 |
| Principal investigator 1 | ModernaTX, Inc. | $14,676.30 | 09/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999077 |
| Principal investigator 1 | ModernaTX, Inc. | $8,325.90 | 09/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,960.00 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,576.40 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,483.80 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,576.40 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,263.40 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,483.80 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,960.00 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,263.40 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,384.40 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,600.40 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,576.40 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684935 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,960.00 | 09/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684941 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,976.02 | 09/26/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192156085 |
| Principal investigator 1 | ModernaTX, Inc. | $1,757.03 | 09/26/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975905 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,538.60 | 09/25/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192153181 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 09/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 09/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 09/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 09/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 09/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699508 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 09/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699586 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,416.00 | 09/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248250716 |
| Principal investigator 1 | ModernaTX, Inc. | $45.50 | 09/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999025 |
| Principal investigator 1 | ModernaTX, Inc. | $151.20 | 09/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999031 |
| Principal investigator 1 | ModernaTX, Inc. | $117.00 | 09/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999033 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,784.43 | 09/23/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250637 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,170.40 | 09/22/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801968 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,281.80 | 09/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248250469 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 09/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248250474 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,100.00 | 09/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248250478 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,250.80 | 09/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248250482 |
| Principal investigator 1 | ModernaTX, Inc. | $884.25 | 09/19/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975891 |
| Principal investigator 1 | ModernaTX, Inc. | $4,419.52 | 09/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999063 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,133.30 | 09/18/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801966 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,093.63 | 09/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250377 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,015.50 | 09/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184240838 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $450.00 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $470.40 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $329.00 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $364.00 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 09/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684945 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $96,565.00 | 09/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248250087 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,690.00 | 09/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248250079 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,225.00 | 09/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665819 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $50.00 | 09/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665848 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,010.00 | 09/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665857 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,500.00 | 09/12/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665771 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,154.60 | 09/12/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249984 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,484.85 | 09/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184236093 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $566.30 | 09/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184236095 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $487.50 | 09/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249782 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,277.00 | 09/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249786 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,259.66 | 09/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249658 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $15,973.20 | 09/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248249667 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $135.00 | 09/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249672 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $15,255.00 | 09/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249676 |
| Principal investigator 1 | ModernaTX, Inc. | $3,074.40 | 09/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999067 |
| Principal investigator 1 | ModernaTX, Inc. | $273.00 | 09/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011592 |
| Principal investigator 1 | ModernaTX, Inc. | $627.90 | 09/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011596 |
| Principal investigator 1 | ModernaTX, Inc. | $23,577.29 | 09/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011612 |
| Principal investigator 1 | ModernaTX, Inc. | $28,509.00 | 09/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011634 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $700.00 | 09/02/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248249373 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $12,110.00 | 09/02/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248249377 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,664.00 | 09/02/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248249381 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 09/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694557 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694575 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694593 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220766368 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,760.10 | 09/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665837 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $27,690.00 | 09/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249323 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,928.60 | 09/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248249327 |
| Principal investigator 1 | ModernaTX, Inc. | $627.90 | 09/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011586 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,159.40 | 08/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,804.20 | 08/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,576.40 | 08/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,960.00 | 08/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,960.00 | 08/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,384.40 | 08/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684873 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $733.60 | 08/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801964 |
| Principal investigator 1 | ModernaTX, Inc. | $43,000.40 | 08/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999055 |
| Principal investigator 1 | ModernaTX, Inc. | $7,827.36 | 08/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999057 |
| Principal investigator 1 | ModernaTX, Inc. | $2,920.68 | 08/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999151 |
| Principal investigator 1 | ModernaTX, Inc. | $9,799.68 | 08/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999161 |
| Principal investigator 1 | ModernaTX, Inc. | $573.04 | 08/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011610 |
| Principal investigator 1 | ModernaTX, Inc. | $1,408.72 | 08/27/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.76 | 08/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 08/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $549.63 | 08/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $262.20 | 08/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 08/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 08/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 08/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 08/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $60.00 | 08/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 08/26/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699506 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 08/26/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760751 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 08/26/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 08/26/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760755 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $305.35 | 08/26/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.85 | 08/26/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760759 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.20 | 08/26/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 08/26/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220766370 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 08/26/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220766372 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,154.60 | 08/26/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249193 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,745.00 | 08/26/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249201 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,312.50 | 08/26/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249204 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,936.00 | 08/25/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665852 |
| Principal investigator 1 | ModernaTX, Inc. | $27,846.00 | 08/25/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011584 |
| Principal investigator 1 | ModernaTX, Inc. | $455.00 | 08/25/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011638 |
| Principal investigator 1 | ModernaTX, Inc. | $16,260.20 | 08/25/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011646 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $16,210.61 | 08/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249020 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,579.60 | 08/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249023 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $390.00 | 08/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249028 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $682.50 | 08/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249032 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $520.00 | 08/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249036 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 08/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249039 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,271.00 | 08/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249043 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,618.00 | 08/21/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192156078 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,490.00 | 08/21/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192156537 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,463.80 | 08/21/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248951 |
| Principal investigator 1 | ModernaTX, Inc. | $5,525.00 | 08/20/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011600 |
| Principal investigator 1 | ModernaTX, Inc. | $3,252.04 | 08/20/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011602 |
| Principal investigator 1 | ModernaTX, Inc. | $941.85 | 08/20/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011636 |
| Principal investigator 1 | ModernaTX, Inc. | $91.00 | 08/20/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011644 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,350.00 | 08/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665799 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,725.00 | 08/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665822 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $12,040.00 | 08/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665840 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,710.00 | 08/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665861 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $12,317.50 | 08/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248795 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $195.00 | 08/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248800 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,221.00 | 08/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248770 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,609.89 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248536 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,050.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248617 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $405.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248621 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $38,272.50 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248625 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $540.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248630 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,455.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248634 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $38,272.50 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248639 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,018.25 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248644 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $25,515.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248647 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,915.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248651 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $540.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248656 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $25,515.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248660 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $810.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248665 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,780.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248669 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,062.50 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248672 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $250.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248676 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,080.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248680 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $70,807.50 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248683 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $21,735.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248688 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $270.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248692 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $50.00 | 08/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248696 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,899.50 | 08/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665779 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,510.00 | 08/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665792 |
| Principal investigator 1 | ModernaTX, Inc. | $1,102.95 | 08/08/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975897 |
| Principal investigator 1 | AstraZeneca UK Limited | $129,895.90 | 08/06/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH II LLC | A Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD2389 CAMPOLINA | No dispute reported | 06/30/2026 | 1185541076 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21,102.35 | 08/06/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801962 |
| Principal investigator 1 | ModernaTX, Inc. | $3,276.00 | 08/06/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999155 |
| Principal investigator 1 | Dexcom, Inc. | $1,395.00 | 08/05/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE | No dispute reported | 06/30/2026 | 1250962266 |
| Principal investigator 1 | Dexcom, Inc. | $2,500.00 | 08/05/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE | No dispute reported | 06/30/2026 | 1250962268 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694565 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694567 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694591 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220766360 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 08/01/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220766362 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 08/01/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220766364 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 08/01/2025 | Non-covered Recipient Entity Arizona Clinical Trials-Tucson | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220766366 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $600.00 | 07/31/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801958 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $140.00 | 07/31/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801960 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,936.00 | 07/31/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665806 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,842.75 | 07/31/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665810 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,919.09 | 07/31/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247914 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,804.20 | 07/30/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684855 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,960.00 | 07/30/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684857 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,960.00 | 07/30/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684859 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,159.40 | 07/30/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684861 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 07/28/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694595 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 07/28/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760739 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 07/28/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 07/28/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760743 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $305.35 | 07/28/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.85 | 07/28/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.20 | 07/28/2025 | Non-covered Recipient Entity Arizona Liver Health | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220760749 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $380.00 | 07/28/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802718 |
| Principal investigator 1 | ModernaTX, Inc. | $2,150.02 | 07/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999051 |
| Principal investigator 1 | ModernaTX, Inc. | $2,507.34 | 07/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999135 |
| Principal investigator 1 | ModernaTX, Inc. | $978.42 | 07/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999143 |
| Principal investigator 1 | ModernaTX, Inc. | $19.76 | 07/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011588 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,690.00 | 07/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801956 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 07/25/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802716 |
| Principal investigator 1 | ModernaTX, Inc. | $2,100.00 | 07/25/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975875 |
| Principal investigator 1 | ModernaTX, Inc. | $900.00 | 07/25/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975877 |
| Principal investigator 1 | ModernaTX, Inc. | $1,757.03 | 07/25/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975879 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 07/25/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975881 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 07/25/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975909 |
| Principal investigator 1 | ModernaTX, Inc. | $1,262.72 | 07/23/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999095 |
| Principal investigator 1 | ModernaTX, Inc. | $1,053.00 | 07/23/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999133 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,139.50 | 07/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184217561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,346.25 | 07/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184217563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.75 | 07/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184217565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,336.50 | 07/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184217567 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $165.00 | 07/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184217569 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $34,941.85 | 07/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247293 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,782.40 | 07/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247297 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $390.00 | 07/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247300 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,179.71 | 07/17/2025 | Non-covered Recipient Entity Arizona Liver Health | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545577 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,018.25 | 07/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247200 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $700.00 | 07/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247204 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $300.00 | 07/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247208 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,207.50 | 07/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247212 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,484.85 | 07/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184216964 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $682.50 | 07/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247081 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,179.80 | 07/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247085 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $29,022.50 | 07/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247089 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $195.00 | 07/16/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247093 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,455.34 | 07/14/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192185666 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,394.32 | 07/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246953 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $48,358.50 | 07/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248246965 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,126.25 | 07/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184214228 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $385.00 | 07/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184214230 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $379.35 | 07/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184214232 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $675.00 | 07/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184214234 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $996.55 | 07/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184214654 |
| Principal investigator 1 | ModernaTX, Inc. | $8,190.00 | 07/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975895 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $80,519.40 | 07/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665786 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $7,020.00 | 07/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665795 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $50.00 | 07/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665815 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,550.00 | 07/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665833 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,000.00 | 07/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665844 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,869.55 | 07/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,211.00 | 07/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184213129 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $159.30 | 07/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184213131 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.50 | 07/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184213133 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $55.00 | 07/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184213135 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4.00 | 07/02/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694581 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694587 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694589 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $11,000.00 | 07/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665775 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,500.00 | 07/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665784 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $6,000.00 | 07/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665789 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,000.00 | 07/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665802 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $43,626.80 | 07/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665828 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,363.50 | 07/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248246273 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $843.75 | 07/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248246278 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $900.00 | 06/27/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15,000.00 | 06/27/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684831 |
| Principal investigator 1 | ModernaTX, Inc. | $730.17 | 06/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999019 |
| Principal investigator 1 | ModernaTX, Inc. | $6,469.32 | 06/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999035 |
| Principal investigator 1 | ModernaTX, Inc. | $16,125.15 | 06/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999037 |
| Principal investigator 1 | ModernaTX, Inc. | $13,045.60 | 06/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999087 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $26,772.90 | 06/26/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801954 |
| Principal investigator 1 | ModernaTX, Inc. | $2,167.43 | 06/25/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 06/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684821 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,000.00 | 06/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,500.00 | 06/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684827 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,828.00 | 06/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684829 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699496 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699498 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699500 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699502 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699504 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699576 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699578 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699580 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699582 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 06/24/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220699584 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $140.00 | 06/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801952 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,629.83 | 06/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246084 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $127,128.35 | 06/23/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211665769 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,427.00 | 06/23/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192149703 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,622.02 | 06/23/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192156545 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,881.50 | 06/20/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245953 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $877.50 | 06/20/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245957 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,629.83 | 06/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245839 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,569.75 | 06/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184209364 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $390.00 | 06/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245754 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,449.50 | 06/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245758 |
| Principal investigator 1 | ModernaTX, Inc. | $2,190.51 | 06/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999045 |
| Principal investigator 1 | ModernaTX, Inc. | $9,570.00 | 06/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999081 |
| Principal investigator 1 | ModernaTX, Inc. | $35,475.33 | 06/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999085 |
| Principal investigator 1 | ModernaTX, Inc. | $18,916.12 | 06/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999089 |
| Principal investigator 1 | ModernaTX, Inc. | $9,636.54 | 06/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011626 |
| Principal investigator 1 | ModernaTX, Inc. | $1,823.97 | 06/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011640 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,657.86 | 06/13/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245619 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,394.32 | 06/12/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245377 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $50.00 | 06/12/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245396 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,036.50 | 06/12/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245400 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $250.00 | 06/12/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245404 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,037.50 | 06/12/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245408 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,609.89 | 06/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244973 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,011.15 | 06/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184204459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,139.50 | 06/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184204461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694543 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $420.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192149698 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $490.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192149720 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192153158 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192153166 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $560.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192153169 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $42.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192153173 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $42.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192153185 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $42.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156068 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $176.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156097 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $132.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156550 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $132.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156553 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $420.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192185647 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192185654 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $44.00 | 05/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192185670 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,216.50 | 05/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684833 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,591.50 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248244602 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $487.50 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248244607 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,085.12 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244616 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $250.00 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244640 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,037.50 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244643 |
| Principal investigator 1 | ModernaTX, Inc. | $1,757.03 | 05/28/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975889 |
| Principal investigator 1 | ModernaTX, Inc. | $37,625.35 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999023 |
| Principal investigator 1 | ModernaTX, Inc. | $32,940.14 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999047 |
| Principal investigator 1 | ModernaTX, Inc. | $9,474.30 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999137 |
| Principal investigator 1 | ModernaTX, Inc. | $55,011.84 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011594 |
| Principal investigator 1 | ModernaTX, Inc. | $255,577.80 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011628 |
| Principal investigator 1 | ModernaTX, Inc. | $29,183.52 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011632 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,969.70 | 05/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184199127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 05/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $730.00 | 05/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.40 | 05/27/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694553 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,480.00 | 05/27/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801950 |
| Principal investigator 1 | ModernaTX, Inc. | $5,050.88 | 05/26/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999107 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,779.08 | 05/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244272 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,090.00 | 05/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244280 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,350.00 | 05/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244284 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $450.00 | 05/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244288 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.14 | 05/20/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699478 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.86 | 05/20/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699480 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.89 | 05/20/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699482 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.52 | 05/20/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699484 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 05/20/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699486 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 05/20/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699488 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.43 | 05/20/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699490 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $195.00 | 05/20/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699492 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.71 | 05/20/2025 | Non-covered Recipient Entity Arizona Liver Health-Peoria Liver Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220699494 |
| Principal investigator 1 | Dexcom, Inc. | $28,091.70 | 05/20/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE | No dispute reported | 06/30/2026 | 1250962262 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,767.89 | 05/19/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156525 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $390.00 | 05/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243765 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $149.50 | 05/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243769 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $20,231.46 | 05/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243777 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $540.00 | 05/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243784 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,240.00 | 05/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243788 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,484.85 | 05/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184195001 |
| Principal investigator 1 | Dexcom, Inc. | $8,667.75 | 05/13/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE | No dispute reported | 06/30/2026 | 1250962264 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15,171.50 | 05/09/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801948 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $420.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192149706 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $42.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192149710 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $42.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192149715 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $907.20 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192149724 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $44.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192153162 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192153177 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156082 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $280.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156089 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $132.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156102 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $420.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156541 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $132.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192185643 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 05/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192185657 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,319.52 | 05/08/2025 | Non-covered Recipient Entity Arizona Liver Health | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545575 |
| Principal investigator 1 | ModernaTX, Inc. | $116.55 | 05/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999017 |
| Principal investigator 1 | ModernaTX, Inc. | $273.00 | 05/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999039 |
| Principal investigator 1 | ModernaTX, Inc. | $806.40 | 05/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999101 |
| Principal investigator 1 | ModernaTX, Inc. | $585.00 | 05/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999165 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $303.75 | 05/06/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248243205 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,993.30 | 05/06/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248243209 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,560.91 | 05/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248243166 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $304.00 | 05/02/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802710 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.00 | 05/02/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802712 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4.00 | 05/02/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802714 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,009.69 | 05/02/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243023 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694531 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,635.00 | 05/01/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801942 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,740.00 | 05/01/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801944 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $335.00 | 05/01/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801946 |
| Principal investigator 1 | ModernaTX, Inc. | $3,103.65 | 05/01/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975887 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $42,619.50 | 04/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248242919 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,090.00 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242778 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $400.00 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242782 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $19,019.44 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248242789 |
| Principal investigator 1 | ModernaTX, Inc. | $38,810.66 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999021 |
| Principal investigator 1 | ModernaTX, Inc. | $1,062.17 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999029 |
| Principal investigator 1 | ModernaTX, Inc. | $8,632.14 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999049 |
| Principal investigator 1 | ModernaTX, Inc. | $1,460.34 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999069 |
| Principal investigator 1 | ModernaTX, Inc. | $2,979.66 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999111 |
| Principal investigator 1 | ModernaTX, Inc. | $93,022.47 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011582 |
| Principal investigator 1 | ModernaTX, Inc. | $1,256.94 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011650 |
| Principal investigator 1 | ModernaTX, Inc. | $82,754.88 | 04/28/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011652 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,742.25 | 04/23/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $766.50 | 04/23/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684837 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,221.40 | 04/23/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684839 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $437.00 | 04/23/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684841 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27.00 | 04/23/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.47 | 04/23/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684845 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.47 | 04/23/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684847 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.47 | 04/23/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.47 | 04/23/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 04/23/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 04/23/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 04/23/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694547 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $21,067.86 | 04/23/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242573 |
| Principal investigator 1 | ModernaTX, Inc. | $3,156.80 | 04/23/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999083 |
| Principal investigator 1 | Dexcom, Inc. | $3,200.00 | 04/15/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE | No dispute reported | 06/30/2026 | 1250962258 |
| Principal investigator 1 | Dexcom, Inc. | $23,888.62 | 04/15/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE | No dispute reported | 06/30/2026 | 1250962260 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,011.15 | 04/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184183264 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,484.85 | 04/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184183266 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,454.44 | 04/10/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156073 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,054.75 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242060 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $50.00 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242064 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242068 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $250.00 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242072 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,052.50 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242077 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $300.00 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242081 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $200.00 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242085 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $135.00 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242089 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $14,242.50 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242092 |
| Principal investigator 1 | Eli Lilly and Company | $1,962.67 | 04/08/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187883552 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $22,905.47 | 04/08/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248241812 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694513 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694519 |
| Principal investigator 1 | ModernaTX, Inc. | $3,784.05 | 04/01/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975893 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $996.55 | 04/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184180610 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 03/25/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 03/25/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 03/25/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694505 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $31,720.50 | 03/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801940 |
| Principal investigator 1 | ModernaTX, Inc. | $2,327.48 | 03/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999053 |
| Principal investigator 1 | ModernaTX, Inc. | $2,190.51 | 03/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999065 |
| Principal investigator 1 | ModernaTX, Inc. | $28,048.04 | 03/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999079 |
| Principal investigator 1 | ModernaTX, Inc. | $8,555.58 | 03/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999113 |
| Principal investigator 1 | ModernaTX, Inc. | $1,499.48 | 03/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999115 |
| Principal investigator 1 | ModernaTX, Inc. | $39,300.29 | 03/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999125 |
| Principal investigator 1 | ModernaTX, Inc. | $61,171.08 | 03/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011598 |
| Principal investigator 1 | ModernaTX, Inc. | $67,486.89 | 03/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011606 |
| Principal investigator 1 | ModernaTX, Inc. | $75,325.12 | 03/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011654 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,104.54 | 03/21/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156533 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 03/21/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192185675 |
| Principal investigator 1 | ModernaTX, Inc. | $6,667.00 | 03/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011616 |
| Principal investigator 1 | ModernaTX, Inc. | $1,881.00 | 03/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011618 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 03/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011642 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,484.85 | 03/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184174312 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,814.75 | 03/14/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248241029 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,877.50 | 03/13/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240879 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $70.00 | 03/12/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801938 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,488.60 | 03/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184170718 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $62,328.19 | 03/06/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240240 |
| Principal investigator 1 | Dexcom, Inc. | $4,921.00 | 03/04/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE | No dispute reported | 06/30/2026 | 1250962256 |
| Principal investigator 1 | Eli Lilly and Company | $29,216.00 | 03/04/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187881618 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,254.50 | 03/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248240084 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $390.00 | 03/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248240088 |
| Principal investigator 1 | ModernaTX, Inc. | $1,757.03 | 03/03/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694489 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694491 |
| Principal investigator 1 | ModernaTX, Inc. | $2,190.51 | 02/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999013 |
| Principal investigator 1 | ModernaTX, Inc. | $10,603.56 | 02/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999071 |
| Principal investigator 1 | ModernaTX, Inc. | $9,359.46 | 02/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999123 |
| Principal investigator 1 | ModernaTX, Inc. | $131,105.04 | 02/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999147 |
| Principal investigator 1 | ModernaTX, Inc. | $10,621.70 | 02/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999149 |
| Principal investigator 1 | ModernaTX, Inc. | $39,136.80 | 02/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999163 |
| Principal investigator 1 | ModernaTX, Inc. | $83,406.96 | 02/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011580 |
| Principal investigator 1 | ModernaTX, Inc. | $150,413.82 | 02/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011604 |
| Principal investigator 1 | ModernaTX, Inc. | $105,790.26 | 02/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011624 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 02/25/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 02/25/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 02/25/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27.60 | 02/25/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694499 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,552.75 | 02/25/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184155578 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,186.00 | 02/24/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192153189 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,186.00 | 02/24/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192156093 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,010.06 | 02/24/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192156519 |
| Principal investigator 1 | Dexcom, Inc. | $20,649.00 | 02/18/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE | No dispute reported | 06/30/2026 | 1250962250 |
| Principal investigator 1 | Eli Lilly and Company | $184,160.00 | 02/18/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187881822 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,053.35 | 02/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184154578 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,075.00 | 02/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184154580 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $220.00 | 02/18/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184154582 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,170.00 | 02/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248239835 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,215.00 | 02/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248239839 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $17,296.50 | 02/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248239843 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,267.50 | 02/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248239847 |
| Principal investigator 1 | AstraZeneca UK Limited | $19,726.00 | 02/12/2025 | Non-covered Recipient Entity ARIZONA CLINICAL TRIALS | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185541074 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $32,805.00 | 02/06/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239069 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $29,310.21 | 02/06/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239076 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,484.85 | 02/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184152554 |
| Principal investigator 1 | Dexcom, Inc. | $2,540.00 | 02/04/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE | No dispute reported | 06/30/2026 | 1250962254 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694469 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694473 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694479 |
| Principal investigator 1 | Eli Lilly and Company | $150.00 | 01/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187881610 |
| Principal investigator 1 | Eli Lilly and Company | $6,152.64 | 01/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882160 |
| Principal investigator 1 | Eli Lilly and Company | $3,859.02 | 01/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187883856 |
| Principal investigator 1 | ModernaTX, Inc. | $2,167.43 | 01/29/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252975899 |
| Principal investigator 1 | ModernaTX, Inc. | $604.89 | 01/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999015 |
| Principal investigator 1 | ModernaTX, Inc. | $136.50 | 01/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999027 |
| Principal investigator 1 | ModernaTX, Inc. | $702.00 | 01/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999043 |
| Principal investigator 1 | ModernaTX, Inc. | $2,525.44 | 01/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999097 |
| Principal investigator 1 | ModernaTX, Inc. | $313.95 | 01/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999119 |
| Principal investigator 1 | ModernaTX, Inc. | $50.40 | 01/29/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999139 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $140.00 | 01/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801934 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,200.00 | 01/28/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801936 |
| Principal investigator 1 | Eli Lilly and Company | $80,677.00 | 01/28/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882072 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $17,024.00 | 01/28/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192185651 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,594.55 | 01/27/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801932 |
| Principal investigator 1 | ModernaTX, Inc. | $30,802.93 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999041 |
| Principal investigator 1 | ModernaTX, Inc. | $17,877.96 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999059 |
| Principal investigator 1 | ModernaTX, Inc. | $9,131.92 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999075 |
| Principal investigator 1 | ModernaTX, Inc. | $2,327.48 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999117 |
| Principal investigator 1 | ModernaTX, Inc. | $3,923.70 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999131 |
| Principal investigator 1 | ModernaTX, Inc. | $1,499.48 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999145 |
| Principal investigator 1 | ModernaTX, Inc. | $765.60 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252999153 |
| Principal investigator 1 | ModernaTX, Inc. | $134,407.50 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011590 |
| Principal investigator 1 | ModernaTX, Inc. | $3,861.78 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011608 |
| Principal investigator 1 | ModernaTX, Inc. | $3,351.84 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011614 |
| Principal investigator 1 | ModernaTX, Inc. | $57,402.80 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011620 |
| Principal investigator 1 | ModernaTX, Inc. | $107,614.23 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011622 |
| Principal investigator 1 | ModernaTX, Inc. | $21,607.52 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011630 |
| Principal investigator 1 | ModernaTX, Inc. | $1,728.20 | 01/27/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011648 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $648.00 | 01/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220684819 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $10,752.50 | 01/23/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238727 |
| Principal investigator 1 | Eli Lilly and Company | $1,201.90 | 01/22/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187881814 |
| Principal investigator 1 | Eli Lilly and Company | $2,898.18 | 01/22/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187881818 |
| Principal investigator 1 | Eli Lilly and Company | $64,556.00 | 01/21/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882070 |
| Principal investigator 1 | Eli Lilly and Company | $29,885.00 | 01/21/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187884008 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,932.40 | 01/21/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184149194 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,226.20 | 01/17/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801928 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,569.75 | 01/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148309 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,000.00 | 01/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148311 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,066.00 | 01/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148313 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,200.00 | 01/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148315 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 01/17/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148317 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,552.75 | 01/14/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184147525 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $77.00 | 01/09/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802704 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.00 | 01/09/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802706 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $228.00 | 01/09/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802708 |
| Principal investigator 1 | Eli Lilly and Company | $8,631.17 | 01/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187881614 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,576.25 | 01/09/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248238171 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $911.25 | 01/09/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248238175 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $16,672.50 | 01/09/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238326 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,312.50 | 01/09/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238329 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,552.50 | 01/09/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238334 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,802.04 | 01/08/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele | No dispute reported | 06/30/2026 | 1185541072 |
| Principal investigator 1 | Dexcom, Inc. | $37,066.00 | 01/07/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITOR (CGM) AND CONTINUOUS LACTATE MONITOR (CLM) IN LIVER DISEASE | No dispute reported | 06/30/2026 | 1250962252 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,880.00 | 01/06/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801930 |
| Principal investigator 1 | Eli Lilly and Company | $23,793.00 | 01/06/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187882156 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,647.42 | 01/06/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248238063 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,009.69 | 01/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248237919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694459 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694465 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Arizona Liver Health-Tucson Liver Clinic | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220694507 |